These have suggested that ACE inhibitors and ARBs reduce the incidence of new-onset AF in a variety of conditions, including hypertension [69, 70], left ventricular dysfunction [71, 72], and after coronary artery bypass graft surgery [73]. The gene discussed is ACE; the disease is atrial fibrillation.